Methods of treatment or prevention of acute brain or nerve injuries
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12042482-B2
Publication Date
2024-07-23
Expiration Date
Abstract
One of the aspects of the invention is directed toward a method of treating or preventing acute brain or nerve injury in a subject, comprising administering an effective amount of posiphen, or a pharmaceutically acceptable salt of posiphen, to the subject in need thereof. Similarly, another aspect of the invention is directed toward a use of posiphen, or a pharmaceutically acceptable salt of posiphen, for the treatment or prevention of acute brain or nerve injury. Preferably, the posiphen in the method or use of the invention is posiphen tartrate.
Core Innovation
The disclosed invention provides a method of treating an acute brain or acute nerve injury in a human subject by administering an effective amount of posiphen, or a pharmaceutically acceptable salt of posiphen. The method is directed to reducing nerve cell death.
A key aspect is timing relative to the acute brain or acute nerve injury episode. Posiphen, or the pharmaceutically acceptable salt thereof, is administered within about 3 days before an episode of the acute brain or acute nerve injury and is thereafter administered for at least 7 days.
The disclosed scope includes acute brain injury types such as traumatic brain injury, and acute nerve injury examples such as acute angle-closure glaucoma. In the described experimental context, posiphen tartrate is evaluated for reducing neuronal cell death and for effects associated with microglial activation and working memory after acute injury paradigms.
Claims Coverage
The independent claim set centers on a method for treating an acute brain or acute nerve injury using posiphen (or a pharmaceutically acceptable salt) with specified timing and administration frequency, with traumatic brain injury identified in the independent claim.
Posiphen administration for acute brain or acute nerve injury
A method of treating an acute brain or acute nerve injury in a human subject by administering an effective amount of posiphen, or a pharmaceutically acceptable salt of posiphen, to reduce nerve cell death, with administration within about 3 days before the episode and thereafter for at least 7 days.
Administration frequency within the first 1-3 days before the episode
Posiphen or a pharmaceutically acceptable salt of posiphen is administered once, twice, three times or four times within the first day, second day or third day before the episode of the acute brain or acute nerve injury occurs.
Traumatic brain injury
The acute brain or acute nerve injury is traumatic brain injury.
Across the independent claim, inventive coverage centers on giving posiphen (or a pharmaceutically acceptable salt) to a human subject for an acute brain or acute nerve injury with a pre-episode window within about 3 days, continuation for at least 7 days, and a dosing frequency limitation during the first 1-3 days before the episode, with traumatic brain injury stated as one embodiment.
Stated Advantages
Reduces nerve cell death.
Documented Applications
Treating acute brain injury, including traumatic brain injury, in a human subject.
Treating acute nerve injury, including acute angle-closure glaucoma.
Interested in licensing this patent?